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Patients with atopic dermatitis (AD) tend to have greatly 
elevated levels of serum immunoglobulin E (IgE). How­
ever, the role of IgE in the pathogenesis of AD is debated. 
This investigator­initiated open­label pilot study evalua­
tes an anti­IgE­treatment approach by combining ex­
tracorporeal immunoadsorption and anti­IgE antibody 
omalizumab in 10 patients with severe, therapy­refrac­
tory AD. IgE levels decreased after immunoadsorption 
and decreased continuously in all patients during anti­
IgE therapy. The reverse trend was observed during 6 
months follow­up without treatment. In parallel with 
these observations, an improvement in AD was observed 
during the treatment period, with aggravation during 
follow­up. Further research is needed, based on the prin­
ciple of reducing IgE levels in order to improve clinical 
symptoms, using a combination anti­IgE treatment ap­
proach, adjusted according to IgE levels. Key words: 
atopic dermatitis; atopic eczema; immunoglobulin E; IgE; 
immunoadsorption; omalizumab; anti-IgE-treatment.
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Atopic dermatitis (AD, atopic eczema) affects 20–30% of 
children and 5–10% of adults in industrialized countries 
(1, 2). AD is associated with concomitant allergic di-
seases, reduces health-related quality of life, and leads 
to considerable economic burden. AD was first noted 
by Roman historian Suetonius in Emperor Octavian 
Augustus, but it was not described fully until the 19th 
century (3). There is no uniformly satisfactory treatment 
for patients who are severely affected by the disease. 
Typically, these patients tend to have greatly elevated 
levels of immunoglobulin E (IgE) (1). However, the role 
of IgE in the pathogenesis of AD is not completely un-
derstood. Studies of treatment with the anti-IgE antibody 
omalizumab have had ambivalent results (4–10). The IgE 
levels in many patients with AD are above the level at 
which an appropriate dose for omalizumab is applicable. 
The aim of the current study is to determine whether 
it is possible to substantially reduce elevated IgE levels 
in AD patients through immunoadsorption, followed 
by appropriate use of omalizumab, and whether this 
sequential treatment has clinically beneficial results. 
To monitor the clinical development of AD, we used 
the Scoring Atopic Dermatitis (SCORAD) index (11) 
and measurement of Thymus and Activation Regulated 
Chemokine (TARC/Human CCL17) levels, which is 
established as an objective parameter for disease seve-
rity in AD (12, 13).
METHODS
This investigator-initiated, open-label pilot study evaluated 10 
patients with severe AD (SCORAD > 50) and greatly elevated 
IgE levels (> 3,500 kU/l) refractory to at least 2 conventional 
systemic treatment options, with a wash-out period of at least 
3 months prior to inclusion in the study. Importantly, if omali-
zumab had been used previously, the interval free of omalizu-
mab had to be more than 6 months. All patients were over 18 
years of age and provided written informed consent. Patients 
with systemic infections, bleeding disorders, or allergies to 
the study material were excluded from the study. The study 
was approved by the local ethics committee and the national 
regulatory agencies, and registered with the EU Clinical Trials 
Register (EudraCT- number 2009-014582-51). Diagnoses were 
made by an experienced dermatologist based on clinical signs 
and symptoms, laboratory findings and personal and family 
history. Informed consent, inclusion and exclusion criteria were 
assessed carefully at a screening visit, which was followed by 
the start of treatment (week 1) within a maximum of 7 days. 
Immunoadsorption and omalizumab
All patients first underwent immunoglobulin apheresis (im-
munoadsorption) depending on their respective baseline IgE 
levels, before starting treatment on 2 (IgE level < 6,000 kU/l), 
3 (IgE level 6,000–20,000 kU/l) or 4 (IgE level > 20,000 kU/l) 
consecutive days, in order to reduce IgE levels as much as 
possible, followed by regular administration of the anti-IgE-
antibody omalizumab every 2 weeks for 24 weeks. After this 
treatment period, the patients were followed up bi-weekly for 
another 24 weeks (Fig. 1). For immunoadsorption, the LIFE 
18 Ig-flex TheraSorb apheresis system (Miltenyi Biotec, Ger-
many) was used, which has adsorption columns containing 
polyclonal sheep antihuman immunoglobulin antibodies and 
binds the different human immunoglobulins, including IgE, 
with similar affinity. Within 20–60 min of completing the im-
munoadsorption setting, omalizumab was administered every 2 
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weeks by subcutaneous injections at a dose of 450 mg (Fig. 1). 
Omalizumab is a recombinant DNA-derived IgG1 humanized 
(from mouse) monoclonal antibody selectively binding to hu-
man IgE and approved by the FDA and international regulatory 
agencies for patients with severe allergic asthma and, recently, 
for chronic spontaneous urticaria (14–16). Besides therapy 
with immunoadsorption and omalizumab, the patients were 
not allowed to receive any other systemic medications for their 
AD. Topical treatments, such as skin care emollients or mild 
topical glucocorticoids (potency class I defined for European 
countries), had to be documented if used.
Clinical and laboratory assessment
Clinical presentation was evaluated with the SCORAD index 
(11) by an experienced dermatologist and with a visual analo-
gue scale (VAS) ranging from 0 (“free of symptoms”) to 100 
(“worst case”) for the subjective severity of AD by the patients 
themselves. IgE and TARC levels were measured for further 
evaluation. On every visit, biologically active IgE (free IgE) 
and TARC were quantified according to standardized protocols 
(R&D Systems, Abingdon, UK) (17, 18), the severity of AD 
was documented with the SCORAD index, and the patient’s 
personal evaluation on the VAS and standardized photographs 
were taken. According to the manufacturer of the system used, 
normal TARC levels in apparently healthy adults range from 71 
to 848 pg/ml. Total IgE was determined using the ImmunoCAP 
system (ThermoFischer/Phadia, Freiburg, Germany). Free 
IgE levels were determined in a lateral flow system (Milenia 
Biotech, Giessen, Germany) using a chimeric molecule based 
on the fusion of the human FcεR1a and avian immunoglobulin 
IgY (17). All statistical analysis was performed using SPSS 
Statistics v.19.0 (IBM Corp., Armonk, NY, USA). 
The primary end-point of the study was a free IgE level below 
150 kU/l, i.e. within the normal range for healthy adults without 
allergic diseases. Secondary end-points were a free IgE level 
below 1,000 kU/l, a reduction in TARC levels, and a clinical 
benefit for the patients measured with SCORAD and VAS.
RESULTS
Characteristics of the patients
From April 2010 to December 2011, 10 patients who 
had previously unsuccessfully undergone 2–4 different 
continuous systemic treatments were enrolled in the 
study. Their baseline characteristics are shown in Table 
I. There were 2 females and 8 males, age range 26–65 
years (mean ± standard deviation (SD) 43.7 ± 11.2 years). 
Nine of 10 patients had allergic rhinitis, 7 of 10 patients 
had asthma. Serum levels of total IgE were in the range 
3,728–69,872 kU/l (mean ± SD 18,094 ± 19,573 kU/l). 
At the time of enrollment, all patients had a SCORAD 
value above 50, internationally recognized as “severe” 
disease. In detail, SCORAD values ranged from 50.2 to 
74.6 (mean ± SD 59.9 ± 8.4). Baseline VAS ranged from 
20 to 90 (56 ± 26.6) (Table I).
IgE during immunoadsorption
During immunoadsorption IgE levels were found to 
be reduced in all patients. Depending on their baseline 
total IgE levels, 3 patients underwent immunoadsorp-
tion on 2 consecutive days, 5 patients on 3 consecutive 
days and 2 patients on 4 consecutive days. Mean ± SD 
IgE levels after the first day of immunoadsorption 
were 10,567 ± 9,393 kU/l, and 7,537 ± 5,716 kU/l 
after the second day. Where applicable, IgE levels 
were 6,933 ± 3,821 kU/l (mean ± SD) after 3 days 
of immunoadsorption and 2,606 ± 1,728 kU/l after 
4 days. After completion of the respective last day 
of immunoadsorption, IgE levels were in the range 
1,384–14,380 kU/l (4,927 ± 4,243 kU/l), and had thus 
reduced by 25.1–94.5%. Mean total IgE levels after 
immunoadsorption were 36 ± 23% of the respective 
values before immunoadsorption.
IgE during omalizumab and follow-up
During the bi-weekly administration of omalizumab, 
levels of biologically active IgE fell continuously, 
Fig. 1. General study design.
Table I. Baseline characteristics of patients enrolled in the study
Patient
Age, 
years/sex
Diagnosis
Prior systemic treatments
Total IgE 
(kU/l)
SCORAD 
(screening)
VAS severity 
(0–100)
TARC 
(pg/ml)Atopic dermatitis Allergic rhinitis Asthma
1 65/M Yes Yes No GCs, UVA 13,989 54.3 20 1,035
2 50/F Yes Yes Yes GCs, UVA, CyA, OMZ 24,494 74.6 90 3,730
3 31/M Yes Yes Yes GCs, UVA, CyA 19,413 73.9 45 410
4 35/M Yes No No GCs, UVA 3,728 62.0 70 355
5 40/M Yes Yes No GCs, UVA, CyA 3,894 54.3 55 2,278
6 49/M Yes Yes Yes GCs, UVA, CyA 6,802 61.0 30 1,955
7 26/M Yes Yes Yes GCs, UVA, CyA, MTX 15,059 55.5 90 2,146
8 48/F Yes Yes Yes GCs, UVA, CyA, OMZ 69,872 50.2 20 3,279
9 45/M Yes Yes Yes GCs, UVA, CyA, OMZ 5,337 53.0 90 3,800
10 48/M Yes Yes Yes GCs, UVA, CyA 18,354 60.1 50 2,379
GCs: glucocorticoids; UVA: phototherapy with ultraviolet UVA-1; CyA: cyclosporin A; OMZ: omalizumab; MTX: methotrexate; SCORAD: clinical index 
SCORing atopic dermatitis (0–103: <25=mild AD, 25–50=moderate AD, >50=severe AD); TARC: Thymus and Activation Regulated Chemokine (TARC/
Human CCL17); VAS severity: severity of atopic dermatitis marked by patients on a visual analogue scale ranging from 0 (“free of symptoms”) to 100 
(“worst case”). Last systemic treatment had to be completed at least 3 months (GCs, UVA, CyA, MTX) or at least 6 months (OMZ) prior to study inclusion.
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reaching free IgE-levels < 150 kU/l in 5/10 and < 1,000 
kU/l in 9/10 patients in the 24 weeks of treatment. After 
stopping the regular application of omalizumab, free 
IgE levels increased again during follow-up, starting in 
week 25, reaching individual levels in week 49 similar 
to pre-study values (Fig. 2). In parallel with the free 
IgE levels, a clinical improvement in AD was observed 
during the treatment period and an aggravation of AD 
during follow-up.
SCORAD and VAS
Just before initiating sequential anti-IgE therapy, the 
SCORAD was 62.0 ± 11.6 (mean ± SD). Two weeks after 
immunoadsorption, a first reduction in SCORAD was 
observed in all 10 patients, with a mean ± SD SCORAD 
of 43.7 ± 9.9 in week 3. Throughout the treatment period, 
the mean ± SD SCORAD continued to decrease, with a 
value of 35.6 ± 13.2 in week 13 (p < 0.01) and 27.2 ± 12.0 
in week 25. A reverse trend occurred during follow-up, 
and on the last visit of our study (week 49) mean ± SD 
SCORAD was 48.7 ± 15.9 (Fig. 2). Individual SCO-
RAD is shown in Table II. In parallel with SCORAD 
a continuous decline in the subjective severity of AD 
measured with VAS was seen throughout the treatment 
period (40.5 ± 14.8 in week 13 and 37.9 ± 18.9 in week 
25) (p < 0.05). Interestingly, VAS values reached almost 
identical levels during follow-up without treatment in 
week 49 (56.7 ± 24.6) compared with baseline VAS be-
fore starting treatment (56.0 ± 26.6). 
Two patients dropped out due to acute exacerbation 
despite anti-IgE therapy in weeks 15 and 17, but were 
included in the follow-up. Despite an initial clinical im-
provement under sequential anti-IgE treatment until week 
13, 1 patient was excluded due to lack of compliance 
in week 15 and absence from follow-up examinations.
TARC
Consistent with the development of the SCORAD index, 
TARC levels decreased during anti-IgE treatment, from 
mean ± SD 2,136 ± 1,187 pg/ml in week 1 before immu-
noadsorption to 1,410 ± 691 pg/ml in week 25 (p < 0.01), 
and increased again during follow-up, with a mean ± SD 
value of 1,748 ± 1,131 pg/ml in week 49 (Fig. 3). It is 
notable that an initial slight increase in TARC values was 
seen in the first weeks after immunoadsorption. 
Adverse events 
During the study temporary dizziness was observed 
during immunoadsorption in 1 patient and 2 of 10 
patients reported fatigue on the days following immu-
noadsorption. Further adverse events were registered 
in 4/10 patients during treatment with omalizumab: 1 
patient reported headaches, 1 reported a slight pain in 
the upper right abdomen, axillary lymph node swellings 
Fig. 2. Mean SCORAD (SCORing Atopic Dermatitis Index) and free 
immunoglobulin E (IgE) levels in the course of study with standard 
deviations before immunoadsorption (week 1), during (weeks 3 and 13), 
and at the end of treatment with omalizumab (OMZ) (week 25) as well as 
after follow-up; n = 10 patients.
Fig. 3. Mean Thymus and Activation Regulated Chemokine (TARC/Human 
CCL17) levels with standard deviations before immunoadsorption (week 
1), during (weeks 3 and 13) and at the end of treatment with omalizumab 
(OMZ) (week 25) as well as after follow-up; n = 10 patients.
Table II. Clinical symptoms of atopic dermatitis (AD) (SCORAD; 
SCORing Atopic Dermatitis Index) over the study period
Pat. No.
Before  
IA
Administration of omalizumab 
(bi-weekly)
Follow up 
(bi-weekly)
Week 1 Week 3 Week 13 Week 25 Week 49
1 54.3 35.0 28.9 Drop out 45.2
2 74.6 49.1 48.2 Lost Lost
3 73.9 47.5 36.0 Drop out 68.3
4 62.0 52.5 22.3 15.4 30.4
5 54.3 32.0 48.5 39.6 29.0
6 61.0 39.7 16.1 12.3 41.4
7 55.5 52.6 52.8 45.8 74.7
8 50.2 29.6 44.8 28.6 37.7
9 53.0 61.6 42.8 32.7 70.8
10 60.1 37.5 16.0 16.3 40.7
Mean ± SD 59.9 ± 8.4 43.7 ± 9.9 35.6 ± 13.2 27.2 ± 12.0 48.7 ± 15.9
IA: immunoadsorption, SD: standard deviation.
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were noticed in 1 patient and 3 patients had elevated 
liver enzymes (aspartate aminotransferase in 3/3, 
maximum 114 U/l; alanine aminotransferase in 2/3, 
maximum 83 U/l; gamma-glutamyl transaminase in 
3/3, maximum 274 U/l). All adverse events ceased and 
normalized spontaneously without medical interference. 
No other adverse events, e.g. infections, were seen.
DISCUSSION
These findings suggest that free IgE can be reduced 
through immunoadsorption prior to treatment with 
omalizumab, and that a therapeutically lowered free 
IgE-level has a clinical benefit in severe AD. These 
findings shed light on the role of IgE in the pathoge-
nesis of some forms of AD. 
Despite some variability in the reduction in IgE bet-
ween individual patients, total IgE could be reduced via 
immunoadsorption in all patients, as seen previously 
(19). After the initial reduction in total IgE levels by 
immunoadsorption, free IgE levels continued to fall 
during regular administration of omalizumab and began 
to increase again during follow-up after anti-IgE therapy 
was stopped. These results were paralleled by TARC 
levels, which have previously been shown to correlate 
with disease severity in AD (12, 13). In parallel with 
free IgE levels, a clinical improvement in AD was 
observed during treatment and an aggravation of the 
skin disease during follow-up (Fig. 2, Fig. S11), which 
suggests that IgE plays a role in the pathogenesis and 
disease “activity” of AD. 
A few studies have used omalizumab and one study 
has used immunoadsorption alone in AD. Whereas 
the latter resulted in a temporary clinical benefit after 
significant reduction in IgE levels in AD (19), studies 
with omalizumab typically had very ambivalent re-
sults: some showed a benefit for patients with AD (4, 
5), some rejected this treatment approach (6, 7) and 
others discussed the high IgE level in AD as a possible 
limitation for a promising use of this anti-IgE antibody 
(8–10). Bearing in mind that omalizumab “inactivates” 
IgE by building immune complexes based on a mole-
cular ratio (20), it cannot be excluded that the dose of 
omalizumab used in the studies mentioned above was 
insufficient to lower biologically active IgE enough to 
have a clinical benefit. 
By initially reducing IgE with immunoadsorption, 
we assume that we reached a condition with a more 
appropriate stoichiometric molar ratio between IgE and 
omalizumab. This enabled the drug to release its known 
anti-IgE effect, seen in the continuous fall in biologi-
cally active IgE in our pilot study during the adminis-
tration of omalizumab, associated with the observed 
clinical benefit. After stopping the anti-IgE treatment, 
biologically active IgE increased again within weeks, 
as did the SCORAD and VAS with worsening eczema. 
This further suggests an association between IgE and 
AD severity in at least some patients. It is believed 
that there are different types (21) or phases (1) of AD 
with differing elevations of IgE; some might be even 
influenced by IgE autoantibodies (22, 23). Our results 
suggest that some of these AD forms, e.g. patients with 
severe AD and grossly elevated IgE levels, may be 
treated successfully with an IgE-targeted approach. In 
the context of up to 40% of placebo-induced clinical 
improvement in patients with AD enrolled in clinical 
trials (3, 4), the findings of our pilot study with only a 
limited number of patients merit further evaluation. In 
addition, the high cost of immunoadsorption (24) and 
omalizumab (25) therapy limit their widespread use and 
currently justify a respective treatment only in patients 
with severe recalcitrant AD. 
The adverse events experienced in our study were all 
expected, except the elevation of liver enzymes during 
omalizumab therapy in 3 out of our 10 patients, which 
is not a typical side-effect of omalizumab. Several pre-
vious publications have described a possible transfer 
of the donor’s IgE-mediated allergies to the recipient 
of liver transplants (26–28) and, although this pheno-
menon cannot yet be explained clearly, an involvement 
of the liver in IgE-mediated allergies is suggested (29, 
30). However, the lowering effect of our study treatment 
on IgE could also affect several aspects of cellular im-
munology, including the liver.
In conclusion, sequential anti-IgE treatment, combi-
ning immunoadsorption and omalizumab in severe re-
fractory AD with highly elevated levels of IgE, appears 
to have an effect on IgE levels and a clinical benefit for 
the patients. To the best of our knowledge, this is the 
first study to combine immunoadsorption and omali-
zumab in treatment of AD. Due to the limited number 
of patients and the open-label design, further studies 
are needed to strengthen the results of this pilot study, 
and our hypothesis that IgE might play an important 
role in the pathogenesis of patients who are severely 
affected by AD. 
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